NASDAQ$TRUP
Trupanion Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Trupanion's Q3 2021 financial results reflected strong momentum and continued growth, with strategic reinvestments in its portfolio.
Trupanion reported a 40% increase in total revenue, reaching $181.7 million in Q3 2021. The company's total enrolled pets increased by 37% year-over-year, while subscription business revenue grew by 28%. Despite these gains, Trupanion experienced a net loss of $(6.8) million, or $(0.17) per share, impacted by increased stock-based compensation and depreciation and amortization.
- Total revenue increased by 40% to $181.7 million compared to Q3 2020.
- Total enrolled pets reached 1,104,376, a 37% increase year-over-year.
- Subscription business revenue grew by 28% to $127.1 million compared to Q3 2020.
- Net loss was $(6.8) million, or $(0.17) per share, impacted by increased stock-based compensation and depreciation and amortization.
Headline financials
Revenue & EPS history
Trupanion · Revenue · Quarterly
$182M
Revenue by segment
Trupanion · $246M total across 2 segments · Q4 2022
- Subscription business$159M+18.2%64.5%
- Other business$87.4M+45.1%35.5%
Forward guidance
The press release contains forward-looking statements related to expectations, plans, prospects and financial results for Trupanion, including expectations regarding its ability to continue to grow its enrollments and revenue, implement its alliance with Aflac and otherwise execute its business plan.
Tailwinds
- Ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods
- Ability to keep growing our membership base and revenue
- Ability to maintain high retention rates
- Effectiveness and statutory or regulatory compliance of our Territory Partner model
- Ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals
Headwinds
- Accuracy of assumptions used in determining appropriate member acquisition expenditures
- Severity and frequency of claims
- Accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency
- Actual claims expense exceeding estimates
- Regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.8%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+2.0%
Avg return
30 days after
46%
19 / 41 earnings
Positive
+28.3%
Q2 2020
Best reaction
-31.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.5% | +3.9% | -9.1% | |
| Q4 2025 | -13.0% | -10.3% | -23.0% | |
| Q3 2025 | -8.4% | -7.6% | -12.3% | |
| Q1 2025 | +23.2% | +22.4% | +29.5% | |
| Q4 2024 | -25.5% | -28.2% | -22.1% | |
| Q3 2024 | +2.9% | -6.0% | +0.1% | |
| Q2 2024 | +13.8% | +21.5% | +29.9% | |
| Q1 2024 | -14.9% | +9.6% | +28.1% | |
| Q4 2023 | -31.3% | -26.8% | -18.6% | |
| Q3 2023 | +27.8% | +11.7% | +43.5% | |
| Q2 2023 | +7.8% | +15.2% | +2.3% | |
| Q1 2023 | -17.5% | -30.8% | -34.2% | |
| Q4 2022 | -0.1% | -3.1% | -7.6% | |
| Q3 2022 | +2.1% | +10.1% | +21.6% | |
| Q2 2022 | +3.0% | +13.2% | +3.7% | |
| Q1 2022 | -7.6% | -0.9% | +0.1% | |
| Q4 2021 | -19.0% | -17.1% | -3.4% | |
| Q3 2021 | +17.0% | +20.8% | +9.2% | |
| Q2 2021 | -13.5% | -13.4% | -20.9% | |
| Q1 2021 | -3.3% | -8.6% | +7.5% | |
| Q4 2020 | -11.2% | -9.9% | -22.2% | |
| Q3 2020 | +0.1% | +17.6% | +37.1% | |
| Q2 2020 | +28.3% | +39.0% | +31.7% | |
| Q1 2020 | -16.1% | -13.9% | -10.3% | |
| Q4 2019 | -17.4% | -9.3% | -22.6% | |
| Q3 2019 | +23.4% | +31.2% | +35.8% | |
| Q2 2019 | -2.6% | -4.8% | -25.9% | |
| Q1 2019 | -1.4% | -1.9% | -11.6% | |
| Q4 2018 | -4.8% | +0.9% | +6.0% | |
| Q3 2018 | +3.0% | -7.7% | -1.3% | |
| Q2 2018 | -3.6% | -7.5% | -7.4% | |
| Q1 2018 | +5.4% | +1.4% | +20.9% | |
| Q4 2017 | -0.0% | -9.2% | +9.5% | |
| Q3 2017 | +13.1% | +11.6% | +3.2% | |
| Q2 2017 | +0.2% | -2.8% | -8.1% | |
| Q1 2017 | +0.9% | +4.7% | +29.0% | |
| Q4 2016 | +3.0% | -2.2% | -10.5% | |
| Q3 2016 | -7.7% | -7.0% | +1.9% | |
| Q2 2016 | -0.3% | -0.6% | -0.5% | |
| Q1 2016 | +13.0% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro